Publications by authors named "M Sako"
Introduction Medical advances and improved living standards have increased life expectancy, and the percentage of older adults is growing rapidly. The proportion of older adults visiting the emergency department (ED) is also increasing. Frailty is recognized as a significant risk factor for adverse outcomes.
View Article and Find Full Text PDFThe design of drug molecules is a critical stage in the drug discovery process. The structure-based drug design has long played an important role in efficient development. Significant progress has been made in recent years in the generation of 3D molecules via deep generation models.
View Article and Find Full Text PDFArticle Synopsis
- * Study Overview: Conducted from 2014 to 2021 at Kati university hospital, the retrospective study included 68 MTEV cases, with a majority (58.8%) being women. Key findings included high clinical probability scores for DVT and significant occurrences of PE.
- * Conclusion on Gender Disparities: The research concluded that women, particularly postpartum, are more affected by MTEV, with a notable recurrence rate and a mortality rate of
Article Synopsis
- The study develops a population pharmacokinetic (PK) model of mycophenolic acid (MPA) specifically for pediatric patients with various diseases, using electronic medical records and previous pharmacokinetic studies.
- A non-linear mixed-effects modeling approach was utilized to estimate key PK parameters such as apparent clearance and volume of distribution while considering patient backgrounds and other variables.
- Analysis of data from 249 patients led to a two-compartment model showing a nonlinear relationship between dosage and MPA exposure, with specific PK parameters estimated for different patient groups.
Background: Three Janus kinase (JAK) inhibitors are approved for ulcerative colitis (UC) in Japan.
Aim: To compare the real-world efficacy and safety of these three JAK inhibitors in UC.
Methods: This was a multicentre, retrospective study of patients with UC started on JAK inhibitors.